Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is safe and feasible for patients with very high-risk solid tumors.

Trial Details

NCT ID
NCT01804634
Phase
PHASE2
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • Cyclophosphamide
  • Fludarabine
  • low dose total body irradiation
  • Melphalan
  • Tacrolimus
Locations (sample)
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • The Bronx, New York, United States|40.84985,-73.86641
  • Valhalla, New York, United States|41.07482,-73.77513

Key Eligibility Criteria

  • Presence of a suitable related HLA-haploidentical bone marrow donor.a. The donor and recipient must be identical at at least one allele of each of …
  • 1 year-50 years
  • Patients must have a confirmed histopathologic diagnosis and be classified as high risk defined by having an expected survival of \< 10%. Examples …
  • Neuroblastoma or ganglioneuroblastoma

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →